Jiacheng Fang

Jiacheng Fang

Auto-generated profile, based on publicly available information

Jiacheng Fang

Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
YZYuxuan Zhang
Yuxuan Zhang
DCDelong Chen
Delong Chen
QDQichao Dong
Qichao Dong
YXYi Xu
Yi Xu
JFJiacheng Fang
Jiacheng Fang
JJJun Jiang
Jun Jiang
Background. The role of a drug-coated balloon (DCB) in the treatment of acute myocardial infarction (AMI) is not well established. Methods. Five databases were searched for randomized controlled trials that compared DCB with stents in the treatment of AMI from their inception to 30 July 2021. The primary clinical endpoint was major adverse cardiac events (MACEs). Summary estimations were conducted using fixed-effects analysis complemented by several subgroups. The protocol was registered with PROSPERO (https://clinicaltrials.gov/ct2/show/CRD42021272886). Results. A total of 4 randomized controlled trials with 485 patients were included. On routine clinical follow-up, DCB was associated with no difference in the incidence of MACEs compared with control (risk ratio [RR] 0.59 [0.31 to 1.13]; ). DCB was associated with similar MACEs compared with drug-eluting stent and lower MACEs compared with bare-metal stent. There was no difference between DCB and control in terms of all-cause mortality, cardiovascular mortality, stent thrombosis, target lesion revascularization, and minimal lumen diameter during follow-up. However, DCB was associated with a lower incidence of myocardial infarction (RR 0.16 [0.03 to 0.90]; ) and lower late lumen loss (mean difference −0.20 [−0.27 to −0.13]; ). Conclusions. In treatment of patients with AMI, DCB might be a feasible interventional strategy versus control as it associated with comparable clinical outcomes. Future large-volume, well-designed randomized controlled trials to evaluating the role of the DCB in this setting are warranted.